has not imposed similar limitations on the securities brokerage activities of bank holding companies. *See* 12 CFR 225.25(b)(15). BNY also contends that riskless principal transactions do not involve the potential conflicts of interests, unsound banking practices and other adverse effects that are sought to be addressed by the Section 20 Firewalls. Furthermore, BNY asserts that compliance with the section 20 Firewalls would place a bank holding company engaged in riskless principal transactions at a competitive disadvantage to other broker-dealers engaged in such activity.

Company, however, would conduct its riskless principal activities subject to the other conditions established by the Board in previous orders, including those conditions that are designed to assure that a bank holding company's riskless principal activities do not constitute the underwriting, public sale, or distribution of securities for purposes of the Glass-Steagall Act. *See Bankers Trust; J.P. Morgan; BankAmerica Corporation*, 79 Fed. Res. Bull. 1163 (1993). For example, Company would engage in riskless principal transactions only in the secondary market and would not engage in riskless principal transactions for any security carried in its inventory. Company also would not act as riskless principal with respect to registered investment company securities or the securities of investment companies advised by BNY or any of its affiliates.

In order to approve the proposal, the Board must determine that the proposed activities to be conducted by BNY ''can reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices.'' 12 U.S.C. 1843(c)(8). BNY believes that the proposal would produce public benefits that outweigh any potential adverse effects. In particular, BNY maintains that the proposal would increase competition for the proposed services.

In publishing the proposal for comment, the Board does not take a position on issues raised by the proposal. Notice of the proposal is published solely to seek the views of interested persons on the issues presented by the application and does not represent a determination by the Board that the proposal meets, or is likely to meet, the standards of the BHC Act. Any comments or requests for hearing should be submitted in writing and received by William W. Wiles, Secretary, Board of Governors of the Federal Reserve System, Washington, D.C. 20551, not later than May 28, 1996. Any request for a hearing on this application must, as required by § 262.3(e) of the Board's Rules of Procedure (12 CFR 262.3(e)), be accompanied by a statement of the reasons why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

This application may be inspected at the offices of the Board of Governors or the Federal Reserve Bank of New York.

Board of Governors of the Federal Reserve System, April 26, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–10907 Filed 5–1–96; 8:45 am]

BILLING CODE 6210–01–F

Change in Bank Control Notices; Formations of, Acquisitions by, and Mergers of Bank Holding Companies; Correction

This notice corrects a notice (FR Doc. 96-9809) published on pages 17704 and 17705 of the issue for April 22, 1996.

Under the Federal Reserve Bank of Atlanta heading, the entry for Bradley County Financial Corp., Cleveland, Ohio, is revised to read as follows:

1. Bradley County Financial Corp., Cleveland, Tennessee; to engage *de novo* through its subsidiary, Tennessee Financial Services, Inc., Cleveland, Tennessee, in consumer finance and insurance agency activities, pursuant to §§ 225.25(b)(1)(i), 225.25(b)(8)(i), and 225.25(b)(8)(ii) of the Board's Regulation Y. The proposed activities will be conducted throughout the States of Tennessee and Georgia.

Comments on this application must be received by May 6, 1996.

Board of Governors of the Federal Reserve System, April 26, 1996.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 96–10908 Filed 5–1–96; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Institute for Occupational Safety and Health Meeting

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Review of the research protocol for the study: ''Evaluation of Prevention Strategies to Reduce Back Pain and Injury Among Nursing Home Workers.''

Time and Date: 1 p.m.–5 p.m., June 5, 1996.

Place: Suncrest Facility, Large Conference Room, NIOSH, CDC, 3040 University Avenue, Morgantown, West Virginia 26505–2888.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 60 people.

Purpose: The purpose of this meeting is to obtain comments and input regarding the technical and scientific merits of the study, ''Evaluation of Prevention Strategies to Reduce Back Pain and Injury Among Nursing Home Workers,'' being conducted by NIOSH. The purpose of the proposed research is to evaluate lifting equipment and medical management programs for their effectiveness in reducing the incidence, cost, and subsequent disability associated with work-related injuries and reports of pain. Participants will review the proposed study protocol, provide recommendations for scientific changes, and provide advice to NIOSH on the conduct of the study. Viewpoints and suggestions from industry, labor, academia, other government agencies and the public are invited. Written comments will be part of the review, and should be received by the contact person listed below no later than May 21, 1996.

Contact Person for Additional Information: James W. Collins, NIOSH, CDC, 1095 Willowdale Road, M/S 1133, Morgantown, West Virginia 26505–2888, telephone 304/285–5998.

Dated: April 25, 1996.

Carolyn J. Russell,

Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 96–10884 Filed 5–1–96; 8:45 am]

BILLING CODE 4160–19–M

Health Care Financing Administration

[R–131]

Agency Information Collection Activities: Proposed Collection; Comment Request

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the

Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Collection Request: Reinstatement, without change, of a previously approved collection for which approval has expired; *Title of Information Collection:* Information Collection Requirements in BPD–458–F, Section 411.408(d)(2) and (f); *Form No.:* HCFA–R–131; *Use:* Physicians who do not accept assignment may bill a patient for services denied by Medicare as ''not reasonable and necessary,'' if they informed the patient, prior to furnishing the services, that Medicare was likely to deny part B payments for services and the patient, after being so informed, agrees to pay for the services. *Frequency:* On occasion; *Affected Public:* Individuals or Households; *Number of Respondents:* 237,322; *Total Annual Responses:* 925,904; *Total Annual Hours Requested:* 115,738.

To request copies of the proposed paperwork collections referenced above, call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections should be sent within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Financial and Human Resources Management Planning and Analysis Staff, Attention: Louis Blank, Room C2–26–17, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

Dated: April 24, 1996.

Kathleen B. Larson,

Director, Management Planning and Analysis Staff, Office of Financial and Human Resources.

[FR Doc. 96–10864 Filed 5–1–96; 8:45 am]

BILLING CODE 4120–03–P

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, and Laboratories That Have Withdrawn From the Program

AGENCY: Substance Abuse and Mental Health Services Administration, HHS (Formerly: National Institute on Drug Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh, Division of Workplace Programs, Room 13A–54, 5600 Fishers Lane, Rockville, Maryland 20857; Tel.: (301) 443–6014.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100–71. Subpart C of the Guidelines, ''Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are *not* to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

Aegis Analytical Laboratories, Inc. 624 Grassmere Park Rd., Suite 21, Nashville, TN 37211, 615–331–5300

Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800–541–4931/205–263–5745

American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 22021, 703–802–6900

Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119–5412, 702–733–7866

Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801–583–2787

Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–227–2783 (formerly: Forensic Toxicology Laboratory Baptist Medical Center)

Bayshore Clinical Laboratory, 4555 W. Schroeder Dr., Brown Deer, WI 53223, 414–355–4444/800–877–7016

Cedars Medical Center, Department of Pathology, 1400 Northwest 12th Ave., Miami, FL 33136, 305–325–5810

Centinela Hospital Airport Toxicology Laboratory, 9601 S. Sepulveda Blvd. Los Angeles, CA 90045, 310–215–6020

Clinical Reference Lab, 11850 West 85th St., Lenexa, KS 66214, 800–445–6917

CompuChem Laboratories, Inc., 3308 Chapel Hill/Nelson Hwy., Research Triangle Park, NC 27709, 919–549–8263/800–833–3984 (Formerly: CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory, Roche CompuChem Laboratories, Inc., A Member of the Roche Group)

CORNING Clinical Laboratories, 4771 Regent Blvd., Irving, TX 75063, 800–526–0947 (formerly: Damon Clinical Laboratories, Damon/MetPath)

CORNING Clinical Laboratories, 875 Greentree Rd., 4 Parkway Ctr., Pittsburgh, PA 15220–3610, 800–284–7515 (formerly: Med-Chek Laboratories, Inc., Med-Chek/Damon, MetPath Laboratories)

CORNING Clinical Laboratories, 24451 Telegraph Rd., Southfield, MI 48034, 800–444–0106, ext. 650 (formerly: HealthCare/Preferred Laboratories, Health Care/MetPath)

CORNING Clinical Laboratories Inc., 1355 Mittel Blvd., Wood Dale, IL